-

Dr. Brandee Pappalardo Joins Fresenius Kabi as Chief Medical Officer for North America

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today that Brandee Pappalardo, Ph.D., M.P.H. has joined the company as senior vice president and Chief Medical Officer for North America. Dr. Pappalardo reports to John Ducker, president and CEO of Fresenius Kabi in North America and is a member of the company’s North America executive committee.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

“I’m very pleased to welcome Brandee to our leadership team at a time when Fresenius Kabi is rapidly expanding its portfolio and customer base in North America,” Ducker said. “Brandee’s experience and leadership style will be integral in helping us engage with the scientific community as we introduce a broad range of new injectable medicines, nutrition therapies, infusion systems, biosimilars and other essential medicines and technologies for U.S. clinicians and patients.”

Dr. Pappalardo comes to Fresenius Kabi from AbbVie, where she worked for more than 16 years in regional and global medical roles of increasing responsibility, most recently as vice president, Immunology, U.S. Medical Affairs. She has deep experience in immunology, including overseeing multiple product launches in rheumatology, dermatology and gastroenterology.

“I’m excited to join Fresenius Kabi and help deliver on the company’s goals to improve access to essential and innovative medicines and technologies,” Dr. Pappalardo said.

Earlier in her career, Dr. Pappalardo was director of the Immunology Core Laboratory at Blood Systems Research Institute in San Francisco where she conducted HIV and HCV research.

She holds a bachelor’s degree in biology from Duke University, a master’s in public health from University of California Berkeley, and a doctorate in immunology from North Carolina State University.

About Fresenius Kabi

Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us.

Contacts

Joanie Clougherty (614) 717-5741
joan.clougherty@fresenius-kabi.com

Fresenius Kabi


Release Versions

Contacts

Joanie Clougherty (614) 717-5741
joan.clougherty@fresenius-kabi.com

More News From Fresenius Kabi

Fresenius Kabi and AABB Announce 21st Annual Blood Collectors Week, September 6–12, 2026, Honoring Lifesaving Blood Collection Professionals

LAKE ZURICH, Ill. & BETHESDA, Md.--(BUSINESS WIRE)--Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) announced today the launch of the 21st annual Blood Collectors Week, taking place September 6–12, 2026. The annual recognition week celebrates the blood collection professionals whose expertise and dedication help ensure patients across the country have access to safe, high-quality blood and blood components. Blood Collectors Week honors the essential pro...

Fresenius Kabi Launches Generic Sugammadex in Simplist® Ready‑to‑Administer Prefilled Syringe in the U.S.

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, a global healthcare company part of the Fresenius Group, specializing in lifesaving therapies and technologies, today announced the U.S. launch of the FDA‑approved generic Sugammadex Injection. Exclusivity for the branded medicine Bridion® (Merck) expired in July 2026. Fresenius Kabi offers operating room clinicians Sugammadex in a Simplist® ready-to-administer prefilled syringe. Simplist® single-dose, prefilled syringes require no assembly at...

Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, an operating company of the Fresenius Group, is recalling one lot of Tyenne® (tocilizumab-aazg) Injection 400 mg/20 mL (20 mg/mL)20 mL vials to the user level. An internal investigation at the firm found the product to contain glass particles. Risk Statement: The administration of an injectable product containing glass particulates may cause local irritation, pain, or swelling at the infusion site, as well as inflammation of the veins. More se...
Back to Newsroom